$0.70
+0.07 (+10.79%)
Open$0.68
Previous Close$0.63
Day High$0.70
Day Low$0.66
52W High$1.50
52W Low$0.37
Volume—
Avg Volume167.8K
Market Cap9.84M
P/E Ratio—
EPS$-1.38
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+2,983.5% upside
Current
$0.70
$0.70
Target
$21.60
$21.60
$19.68
$21.60 avg
$29.43
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 10.80M | 8.27M | 3.80M |
| Net Income | -17,907,738 | -12,346,379 | 985.2K |
| Profit Margin | -800.8% | -760.7% | 25.9% |
| EBITDA | -27,263,767 | -19,841,105 | 1.34M |
| Free Cash Flow | — | — | 1.13M |
| Rev Growth | +30.5% | +30.5% | +24.5% |
| Debt/Equity | 0.95 | 0.95 | 1.00 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $249.68 | -0.45% | 118.6 | 430.95B |
| AMGN | Amgen Inc | $412.84 | -1.20% | 25.1 | 219.39B |
| GILD | Gilead Sciences Inc | $138.12 | -0.01% | — | 165.85B |
| VRTX | Vertex Pharmaceuticals Inc | $508.33 | -1.57% | 28.3 | 124.51B |
| REGN | Regeneron Pharmaceuticals | $803.64 | -0.29% | 18.4 | 79.53B |
| ALNY | Alnylam Pharmaceuticals Inc | $227.29 | +0.07% | 35.2 | 28.41B |